F-Prime’s Post

Congratulations to Atalanta Therapeutics for naming Joanne Dove Kotz as Chief Executive Officer and a member of the Board of Directors, succeeding Alicia Secor, MBA, who has stepped down. Since their founding, Atalanta has emerged as a leader in the development of RNA interference-based therapies for central nervous system diseases. Being early supporters, we’ve had the honor to support Atalanta through the advancement of multiple investigational therapies toward clinical trials—with potential to make a real impact on devastating neurological diseases. “We thank Alicia for her extraordinary leadership from formation to the cusp of the clinic—and are thrilled to welcome Joanne as she leads Atalanta into its next chapter.” – Dr. Stephen Knight, President and Senior Managing Partner, F-Prime Click the link in the comments to learn more! #AtalantaTX #RNALeaders Stephen Knight, M.D. | Stacie Weninger, Ph.D. | Jessica Alston, Ph.D.